At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.6×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
669.14MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.31xvs all stocks
52-Week Change
39.96%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
669.14MUSDvs all stocks (USD)
Enterprise Value
495.48MUSDvs all stocks (USD)
Forward P/E
-9.95xvs Biotechnology peers
Enterprise to EBITDA
-8.54xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-29.21%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Oct 26, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-58.05MUSDvs all stocks (USD)
Net Income (TTM)
-114.04MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-47.02MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-54.88MUSDvs all stocks (USD)
Pre-tax Income
-54.65MUSDFY2025 · Dec 31, 2025Net Income
-54.65MUSDFY2025 · Dec 31, 2025EBIT
-53.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-53.19MUSDFY2025 · Dec 31, 2025Research & Development
23.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
31.88MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
819.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.25USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.25USDFY2025 · Dec 31, 2025Basic Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-54.65MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-46.28MUSDFY2025 · Dec 31, 2025Free Cash Flow
-46.29MUSDDerived from operating cash flow minus capital expenditure. This filing charges 228K of depreciation against 4K of capital expenditure, and its own free-cash-flow line reads -49.47M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.95MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-54.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
228.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.76MUSDFY2025 · Dec 31, 2025Other Non-cash Items
460.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.08MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
-4.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-24.75MUSDFY2025 · Dec 31, 2025Sale of Investments
30.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
6.11MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
50.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
102.66MSharesUpdated Oct 26, 2026Float Shares
74.69MSharesUpdated Oct 26, 2026Shares Short
17.47MSharesUpdated Oct 26, 2026Short Ratio
10.47daysvs all stocks
Short % of Shares Outstanding
17.08%vs all stocks
% Held by Insiders
0.91%vs all stocks
% Held by Institutions
82.23%vs all stocks
Total Cash (MRQ)
187.30MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.82USDUpdated Oct 26, 2026Total Debt (MRQ)
14.95MUSDvs all stocks (USD)
Current Ratio (MRQ)
0.9530xvs Biotechnology peers
Book Value per Share (MRQ)
-0.1430USDUpdated Oct 26, 2026Total Assets
41.79MUSDvs all stocks (USD)
Total Current Assets
39.89MUSDFY2025 · Dec 31, 2025Total Liabilities
20.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
11.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.08MUSDFY2025 · Dec 31, 2025Cash
639.00KUSDFY2025 · Dec 31, 2025Cash Equivalents
20.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
15.47MUSDFY2025 · Dec 31, 2025Accounts Payable
867.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.56MUSDFY2025 · Dec 31, 2025Long-term Debt
11.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
121.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-260.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
21.52MUSDvs all stocks (USD)
52-Week Low
2.62USDUpdated Oct 26, 202652-Week High
8.64USDUpdated Oct 26, 202652-Week Change
39.96%vs all stocks
Beta
2.31xvs all stocks
50-Day MA
7.55USDUpdated Oct 26, 2026200-Day MA
5.61USDUpdated Oct 26, 2026Avg 10-Day Volume
1.44MSharesUpdated Oct 26, 2026Avg 30-Day Volume
1.47MSharesUpdated Oct 26, 2026Diluted EPS (TTM)
-1.69USDUpdated Oct 26, 2026Other Income / Expense
-444.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.95×, lower than 95% of its Biotechnology peers (median 5.6×)Significant
Current ratio: 0.95Industry median: 5.60Industry P5: 1.03Peers compared: 245
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Altman Z-Score 7.72: safe zoneNotable
Altman Z-Score: 7.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 37,231,057.061
Companies that share the same coordination system — how they create, deliver, or capture value.
Immix Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sd Biosensor Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Solid Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Getein Biotech Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lexicon Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule